Dystrophin expression in muscle following gene transfer with a fully deleted ("Gutted") adenovirus is markedly improved by Trans-acting adenoviral gene products by Gilbert, R. et al.
HUMAN GENE THERAPY 12:1741–1755 (September 20, 2001)
Mary Ann Liebert, Inc.
Dystrophin Expression in Muscle Following Gene Transfer
with a Fully Deleted (“Gutted”) Adenovirus Is Markedly
Improved by Trans-Acting Adenoviral Gene Products
RÉNALD GILBERT,1 JOSÉPHINE NALBANTOGLU,1 JOHN MCC. HOWELL,2 LINDA DAVIES,2
SUSAN FLETCHER,3 ANDREA AMALFITANO,4 BASIL J. PETROF,5 AMINE KAMEN,6
BERNARD MASSIE,6 and GEORGE KARPATI1
ABSTRACT
Helper-dependent adenoviruses (HDAd) are Ad vectors lacking all or most viral genes. They hold great promise
for gene therapy of diseases such as Duchenne muscular dystrophy (DMD), because they are less immuno-
genic than E1/E3-deleted Ad (first-generation Ad or FGAd) and can carry the full-length (Fl) dystrophin (dys)
cDNA (12 kb). We have compared the transgene expression of a HDAd (HDAdCMVDysFl) and a FGAd
(FGAdCMV-dys) in cell culture (HeLa, C2C12 myotubes) and in the muscle of mdx mice (the mouse model
for DMD). Both vectors encoded dystrophin regulated by the same cytomegalovirus (CMV) promoter. We
demonstrate that the amount of dystrophin expressed was significantly higher after gene transfer with FGAd-
CMV-dys compared to HDAdCMVDysFl both in vitro and in vivo. However, gene transfer with HDAd-
CMVDysFl in the presence of a FGAd resulted in a significant increase of dystrophin expression indicating
that gene products synthesized by the FGAd increase, in trans, the amount of dystrophin produced. This en-
hancement occurred in cell culture and after gene transfer in the muscle of mdx mice and dystrophic golden
retriever (GRMD) dogs, another animal model for DMD. The E4 region of Ad is required for the enhance-
ment, because no increase of dystrophin expression from HDAdCMVDysFl was observed in the presence of
an E1/E4-deleted Ad in vitro and in vivo. The characterization of these enhancing gene products followed by
their inclusion into an HDAd may be required to produce sufficient dystrophin to mitigate the pathology of
DMD by HDAd-mediated gene transfer.
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OVERVIEW SUMMARY
Adenovirus (Ad) deleted of all viral genes (helper-depen-
dent Ad, HDAd) are less immunogenic then E1-deleted Ad
(first-generation, FGAd). HDAd are consequently viewed
as better vectors to treat disease such as Duchenne mus-
cular dystrophy (DMD). In this report we demonstrate
that the expression level of dystrophin carried by a HDAd
is significantly lower compared to a FGAd. This observa-
tion was made in cell culture and after gene transfer in
muscles of two animal models of DMD. We further show
that FGAd synthesizes gene products that enhance its own
transgene expression, as well as the transgene expression
of HDAd when provided in trans. The E4 region was es-
sential for this enhancement, because no increase of dys-
trophin expression by a HDAd occurred in the presence
of an E1/E4-deleted Ad. The characterization and inclu-
sion of these enhancing factors into a HDAd might be nec-
essary for efficient treatment of DMD by HDAd-mediated
gene therapy.
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INTRODUCTION
REPLICATION-INCOMPETENT ADENOVIRUS (Ad) rendered de-fective because of deletion of the essential E1 region, also
known as first generation Ad (FGAd) possess several proper-
ties that make them a very attractive vector for gene therapy
application. For example, they can easily be produced to very
high titer, they have a wide tropism, they can transduce both
mitotic and post-mitotic cells and, depending of the tissue or
the animal model under investigation, they can provide very
high transduction level (reviewed in Karpati et al., 1997; Ragot
et al., 1997). Unfortunately, gene transfer using FGAd in im-
munocompetent animals resulted only in temporary expression
of the transgene, because of an immune response of the host
that eliminates the transduced cells or that silences the trans-
gene expression (Dai et al., 1995; Gilgenkrantz et al., 1995;
Lochmuller et al., 1996; Yang et al., 1996; Guibinga et al.,
1998; Howell et al., 1998). The transgene antigenicity (Tripa-
thy et al., 1996; Michou et al., 1997; Yang et al., 1996) as well
as low grade synthesis of Ad gene products (Yang et al.,
1994a,b), have been shown to be responsible for triggering the
deleterious immune response.
One approach to reduce the immune response caused by the
leaky expression of viral gene products was to delete additional
viral genes such as E4 (Gao et al., 1996; Armentano et al.,
1997; Brough et al., 1997; Dedieu et al., 1997; Wang et al.,
1997; Lusky et al., 1998) or E2 (Engelhardt et al., 1994; Yang
et al., 1994b; Hu et al., 1999; Hodges et al., 2000). A more
drastic approach has been to remove all viral sequences except
for the inverted terminal repeats (ITR) and the packaging sig-
nal (Fisher et al., 1996; Kochanek et al., 1996; Kumar-Singh
and Chamberlain, 1996; Parks et al., 1996; Kochanek, 1999).
Such completely deleted Ad vectors are often referred to as
“gutted Ad,” large capacity Ad or helper-dependent Ad
(HDAd). Deletion of additional Ad genes in these vectors has
been associated with a reduction of cellular immune response,
which has often lead to an improvement in the duration of the
transgene expression (Gao et al., 1996; Wang et al., 1997;
Morsy et al., 1998; Schiedner et al., 1998; Chen et al., 1999;
Hu et al., 1999; Maione et al., 2000). However, in immunode-
ficient animals, several reports have documented a reduction or
a rapid loss of transgene expression after gene transfer with Ad
vectors lacking, in addition to E1, the E4 or E2 regions (Lieber
et al., 1996; Armentano et al., 1997; Brough et al., 1997; Lieber
et al., 1997; Dedieu et al., 1997; Lusky et al., 1998, 1999). An-
other advantage of using Ad with large deletion, is the propor-
tional gain in their transport capacity, which, in the case of a
fully deleted HDAd has increased to approximately 36 kb.
Duchenne muscular dystrophy (DMD) is a fatal disease char-
acterized by a progressive loss of skeletal muscle fibers lead-
ing to death usually by the age of 25 (Engel et al., 1994). DMD,
which affects 1 of 3,500 male births, is caused by mutation of
the gene encoding dystrophin, a rod-shaped cytoskeletal pro-
tein associated with the inner face of the plasma membrane of
muscle (Sadoulet-Puccio and Kunkel, 1996). Although no ef-
fective treatment exists for DMD, one promising approach for
treating this disease is gene replacement by Ad-mediated dys-
trophin gene transfer. Several groups have demonstrated the po-
tential usefulness of this approach in preclinical studies using
mdx mice, the mouse model for DMD (Vincent et al., 1993;
Acsadi et al., 1996; Deconinck et al., 1996; Yang et al., 1998),
and in the dystrophin-deficient golden retriever (GRMD) dog
model (Howell et al., 1998). We have also demonstrated that
Ad-mediated utrophin gene transfer, utrophin being a functional
dystrophin homologue, could equally well mitigate the dys-
trophic phenotype of the mdx muscle (Gilbert et al., 1999; Ebi-
hara et al., 2000; Wakefield et al., 2000). However, as discussed
above, dystrophin and utrophin expression after gene transfer
with FGAd in immunocompetent animals was temporary due
in large measure to the host cellular immune response against
transduced fibers.
In an attempt to improve the duration of dystrophin expres-
sion after gene transfer in muscle, we have constructed a HDAd
deleted of all viral genes and encoding dystrophin regulated by
the cytomegalovirus (CMV) promoter (HDAdCMVDysFl).
Surprisingly, in comparison to a FGAd encoding the dystrophin
regulated by the same promoter (FGAdCMV-dys), the amount
of dystrophin produced was significantly lower after gene trans-
fer with HDAdCMVDysFl in vitro and in the muscle in vivo.
We demonstrate that a marked increased of dystrophin pro-
duction by HDAdCMVDysFl occurs in the presence of Ad gene
products in cell culture and in the muscle of mdx mice and
GRMD dogs, two animal models for DMD. We show that the
E4 region is required for the enhancement, because no increase
of dystrophin expression was observed in the presence of an
E1/E4-deleted Ad. These observations have important implica-
tions for the design of Ad vectors for potential use in clinical
trials for DMD or for other genetic diseases requiring abundant
expression of a therapeutic transgene in muscle. In the case of
DMD, the characterization of these adenoviral gene products,
followed by their inclusion into the backbone of a HDAd, may
be needed to produce sufficient dystrophin to mitigate the 
dystrophic phenotype of the diseased muscle.
MATERIALS AND METHODS
First- and second-generation adenovirus
Unless stated otherwise, all cells were grown in Dulbecco’s
modified Eagle medium (DMEM, Life Technologies, Burling-
ton, Ontario, Canada) supplemented with 30 mg/ml gentamicin,
20 mM L-glutamine and 10% fetal bovine serum (BioWhittaker,
Walkersville, MD) under an atmosphere of 5% CO2.
The FGAd (E1/E3-deleted) encoding either b-galactosidase
(FGAdCMV-lacZ) or the minidystrophin cDNA modeled on
the Becker gene (FGAdCMV-dys) have been described previ-
ously (Acsadi et al., 1994, 1996; Jani et al., 1997). Ad5/dE1(b-
gal)dE4 is an E1/E4-deleted Ad that expresses b-galactosidase
regulated by the phosphoglycerate kinase promoter (Wang et
al., 1995). The E4 region of Ad5/dE1(b-gal)dE4 is only par-
tially deleted, because open reading frame 4 (ORF4) is ex-
pressed. The Ad vectors were isolated by centrifugation on two
consecutive discontinuous CsCl gradients using standard
method of purification (Acsadi et al., 1994). The CsCl was re-
moved by chromatography on Sephadex G25 columns (Amer-
sham Pharmacia Biotech Inc, Piscataway, NJ) and eluted with
phosphate-buffered saline (PBS). The titer (virus particles/mil-
liliter) was determined from the optical density at 260 nm (Mit-
tereder et al., 1996). When not used the same day, the viral
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preparations were kept at 280°C in PBS supplemented with
10% glycerol, 0.1% bovine serum albumin (BSA), 10 mM Tris-
HCl (pH 7.2), and 5 mM MgCl2. Before injection, the glycerol
was removed by chromatography on Sephadex-G25. The in-
fectious titer of FGAdCMV-lacZ and Ad5/dE1(b-gal)dE4 was
determined by calculating the number of b-galactosidase posi-
tive cells (blue-forming unit, BFU) at 20 hr following infection
of 293A cells in 30-mm dishes with grids (Sarstedt, Newton,
NC), as described previously (Wang et al., 1995). The infec-
tious titer of FGAdCMV-dys was determined by measuring the
cytopathic effect after serial dilution on 293A cells (Nyberg-
Hoffman et al., 1997) and by in situ hybridization (see below).
The ratio of virus particles to infectious particles was 50:1 for
both FGAdCMV-lacZ and Ad5/dE1(b-gal)dE4, and 100:1 for
FGAdCMV-dys.
Construction of HDAdCMVDysFl
To construct a HDAd expressing the full-length human dys-
trophin regulated by the CMV promoter and enhancer (HDAd-
CMVDysFl), plasmids pCMVDysFl and pUClI were first gen-
erated using standard methods of molecular biology (Sambrook
et al., 1989). Plasmid pCMVDysFl was made by inserting the
following DNA fragments into the multiple cloning site of
pBluescript (Stratagene, La Jolla, CA): a unique Not I site, the
ITR and the packaging sequence of Ad type V, as well as the
rabbit b-globin poly(A) signal derived from pAdCMV-dys (Ac-
sadi et al., 1996; Jani et al., 1997), the full-length human dys-
trophin cDNA (Acsadi et al., 1991), the immediate early pro-
moter and enhancer of human CMV (position -508 to 170 from
the transcription initiation site), and a unique Sal I restriction
site. The CMV promoter was obtained by PCR of p-CMVLacZ
(Acsadi et al., 1994) using primers 59-TGCACGTCGA-
CATAACTTACGGTAAATGG-3 9 and 59-GCTAACTAGTG-
GAGGCTGGATCGGTC-3 9. Digestion of pCMVDysFl with
Not I and Sal I releases the left ITR and the dystrophin ex-
pression cassette. Plasmid pUClI was constructed by inserting
the following DNA fragments into pUC19 (MBI Fermentas,
Burlington, Ontario, Canada), a unique Xho I site, the 16.8-kb
Bam HI fragment of lambda DNA (position 5,505—22,346),
the last 250-bp of Ad type 5 encoding the right ITR followed
by a unique Hind III site. The right ITR was obtained by 
PCR of purified DNA (Graham and Prevec, 1991) of FGAd-
CMV-lacZ using primers 59-TACGTGTCGACACAACTTC-
CTCAAATCG-39 and 59-CGAGCCTCGAGCATCATCAAT-
AATATACC-39. The lambda DNA stuffer and the right ITR
can be released by digesting pUClI with Xho I and Hind III.
HDAdCMVDysFl was generated by ligating 7 mg of purified
Not I/Sal I fragment of pCMVDysFl with 14 mg of purified Xho
I/Hind III fragment of pUClI overnight at 16°C in 100 ml, and
extracted by phenol/chloroform followed by ethanol precipita-
tion. Before ligation, the Not I, Xho I and Hind III ends were
dephosphorylated by treatment with calf alkaline phosphatase
(New England BioLabs Inc, Mississauga, Ontario, Canada) and
purified by electrophoresis on low-melting-point agarose fol-
lowed by phenol/chloroform extraction and ethanol precipita-
tion. Six micrograms of ligation product was used to transfect
a 60-mm dish of 293Cre4 cells (Parks et al., 1996) with Lipo-
fectAMINETM (Life Technologies, Burlington, Ontario,
Canada) according to the manufacturer’s recommendations.
The next day, the cells were infected with the helper virus
(AdLC8cluc) (Parks et al., 1996) and harvested 2 days later.
The vector was amplified by consecutive passages on 293Cre4
cells as described previously (Parks et al., 1996). The presence
of HDAdCMVDysFl in the cell lysate was verified by dot blot
hybridization (Jani et al., 1997) and by in situ hybridization (see
below) using probe specific for dystrophin or the lambda stuffer.
The virus was purified by two rounds of CsCl buoyant density
centrifugation as described (Hitt et al., 1995). The CsCl was
removed by chromatography on Sephadex G25 columns (Amer-
sham Pharmacia Biotech Inc, Piscataway, NJ) and eluted with
PBS. The titer (virus particles/ml) was determined from the op-
tical density at 260 nm (Mittereder et al., 1996). The contam-
ination level by AdLC8cluc, which was 0.1% or less depend-
ing on the viral preparation, was determined by measuring the
cytopatic effect after serial dilution on 293A cells (Nyberg-
Hoffman et al., 1997). The infectious titer of HDAdCMVDysFl
was measured by in situ hybridization (see below). The ratio of
virus particles to infectious particles was 100:1. The structure
of the viral DNA was confirmed by restriction analysis of pu-
rified DNA (Graham and Prevec, 1991) followed by agarose
gel electrophoresis. The gel was stained using SYBR® Gold
(Molecular Probes, Inc. Eugene, OR) and analyzed on a phos-
phoimager (STORM, Molecular Dynamics Inc).
In situ hybridization
In situ hybridization was accomplished using modifications
of published methods (Guiot and Rahier, 1995). Briefly, eight-
well Permanox® Chamber Slide™ (Nalge Nunc International,
Naperville, IL) coated with 0.01% collagen (Roche Molecular
Biochemicals, Laval, Quebec) were seeded with 3.03 104 of
293A cells. The next day, the cells were infected with 100 ml
of various virus dilutions in growth medium containing helper
virus (AdLC8cluc) at a multiplicity of infection (MOI) of 3 in-
fectious particles. Helper virus was added to promote replica-
tion of viral DNA to increase the number of DNA copies and
thus the signal intensity. After 1 hr, 200 ml of growth medium
was added and the cells were incubated overnight at 37°C. All
subsequent manipulations were accomplished at room temper-
ature unless stated otherwise. The cells were fixed with 2% glu-
taraldehyde for 10 min, permeabilized with 1% Triton X-100
for 10 min, and treated with 30 mg/ml of proteinase K (Roche
Molecular Biochemicals, Laval, Quebec) in PBS for 15 min at
37°C. The cells were then treated with 0.023 N HCl for 5 min,
fixed with 2% glutaraldehyde for 10 min and incubated for 2–4
hr at 37°C with prehybridization buffer [50% (vol/vol.) for-
mamide, 20% (wt/vol) dextran sulfate, 4 3 SSC, 2% (vol/vol)
Denhardt’s solution, 100 ug/ml sheared herring sperm DNA].
Thirty microliters of diluted denatured probe in prehybridiza-
tion buffer was added to each chamber and incubated overnight
at 37°C. The probes (purified DNA fragments of dystrophin
cDNA or phage lambda stuffer) were labeled with a random
primer fluorescein labeling kit (NEN™ Life Science Products,
Boston, MA) according to the manufacturer’s recommenda-
tions. The next day, the cells were washed with 4x SSC/30%
formamide, incubated with a biotin conjugated monoclonal anti-
fluorescein isothiocyanate (FITC) antibody (clone FL-D6,
Sigma, St. Louis, MO) followed with horseradish peroxidase
conjugated to streptavidin (Vector Laboratories, Inc. Bur-
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lingame, CA). The peroxidase activity was revealed by im-
mersion in the AEC Turbo Reagent (DAKO Diagnostics, Mis-
sissauga, Ontario, Canada), and mounted in Immuno-Mount
(Shandon Lipshow, Pittsburgh, PA). The infectious titer was
determined by calculating the percentage of positively labeled
nuclei multiplied by the dilution factor.
Western blot analysis
HeLa cells were seeded at 0.53 105 cells in 3-cm dishes and
infected the next day with Ad vectors at various MOI in 1 ml
of medium. One milliliter of medium was then added, the cells
were incubated for 4 days, lysed with 150 ml of sample buffer
consisting of 62 mM Tris-HCl (pH 6.8), 4% sodium dodecyl
sulfate (SDS), 10% glycerol, 0.02% bromophenol blue, 10 mM
phenylmethylsulfonyl fluoride (PMSF), 2.5 U aprotinin/ml, 0.5
mg leupeptin/ml and boiled for 4 min. The nuclear DNA was
sheared by 20 passages through a 22G1 1/2 needle. The pro-
tein concentration was determined and the samples were
processed for western blot analysis as described previously
(Gilbert et al., 1998), using a monoclonal antibody specific for
the carboxyl terminus of dystrophin (NCL-DYS2, Novocastra,
Newcastle upon Tyne, UK).
For infection of culture of muscle cells, C2C12 myoblasts
were plated in 3-cm dishes at a density of 1.5 3 105 cells/dish.
The next day, the medium was replaced with differentiation
medium (DMEM supplemented with 30 mg/ml gentamicin, 20
mM L-glutamine, and 2% horse serum) and incubated for 4 days.
At that time, well-differentiated myotubes had formed (although
there were still nondifferentiated myoblasts in the culture) and
the cells were infected with various MOI of Ad vectors in 1 ml
of differentiation medium. It was assumed that 3.03 105 cell
nuclei were present at the time of infection. One hour later, 1
ml of differentiation medium was added and the cells were in-
cubated for 4 days, before being processed for western blot anal-
ysis as described above using a monoclonal antibody specific
for the human dystrophin (NCL-DYS3, Novocastra, Newcastle
upon Tyne, UK).
Isolation of viral DNA and quantification by dot blot
analysis and by PCR
HeLa cells or C2C12 myotubes were infected as described
above. At 4 days post-infection, the viral DNA was isolated
(Hirt, 1967) and processed for dot blot analysis (Jani et al.,
1997) using a 32P-labeled lambda stuffer DNA fragment as a
probe. The signal was visualized and quantified using a phos-
phoimager (STORM, Molecular Dynamics).
The quantity of vector DNA after gene transfer in the mus-
cle was determined by semiquantitative PCR as described pre-
viously (Chen et al., 1999). Briefly, DNA samples were ex-
tracted from 50 cryostat sections of muscles injected with
HDAdCMVDysFl, with a mixture of HDAdCMVDysFl/
FGAdCMV-lacZ , or with a mixture of HDAdCMVDysFl/Ad5/
dE1(b-gal)dE4. A total of 50 ng of DNA was amplified by Taq
DNA polymerase and two primer sets. One primer set was spe-
cific for the lambda stuffer or for b-galactosidase, the other
primer set was specific for the mouse adipsin gene, which is an
internal control of input DNA. A standard curve was made us-
ing 50 ng of DNA of PBS-injected muscle spiked with known
amount of pUClI or pCMVb (Clontech Laboratories, Inc., Palo
Alto, CA) and amplified in parallel. The lambda primer pair,
59-GGCGTACTGACGGATTC-3 9 and 59-CAGTTCAAGAC-
GACGCAG-39, was specific for a sequence between nucleo-
tides 19,542 and 19,973 of bacteriophage lambda, giving a 432-
bp PCR product (GenBank accession number J02459). The
b-galactosidase primer pair, 59-TGCTGCGTTGGAGTGAC-3 9
and 59-CAGTTCAACCACCGCAC-3 9, was specific for a se-
quence between nucleotide 1,507 and 1,889 of the b-galactosi-
dase gene giving a 383-bp PCR product (GenBank accession
number U02451). PCR reactions were performed in 25 ml con-
taining 1 mM MgCl2, 10 mM Tris-HCl (pH 8.8), 50 mM KCl,
0.08% Nonidet P40, 4 mM of each primer, 0.2 mM of each
dNTP, and 1.25 units of Taq DNA polymerase. Amplification
was carried out for 28 cycles at 94°C for 30 sec, 57°C for 1
min , 72°C for 1 min, followed by a single extension at 72°C
for 10 min. The DNA was analyzed by electrophoresis on 1.8%
agarose gel, stained with SYBR® Gold (Molecular Probes, Inc.
Eugene, OR), and analyzed on a phosphoimager (STORM, Mo-
lecular Dynamics Inc). SYBR® Gold is a fluorescent nucleic
acid stain that can be used to quantify DNA after agarose gel
electrophoresis by gel scanner systems (Tuma et al., 1999;
Even-Chen and Barenholz, 2000). The standard curve was lin-
ear over the range of DNA used in the study and all the values
were normalized to the adipsin signal.
Intramuscular injection and histochemistry
All animal experiments were performed according to McGill
and Murdoch universities guidelines for animal care. For ex-
periments using mdx mice, the left and right tibialis anterior
muscles (TA) of neonatal (2- to 4-day-old) or young adult (4-
week-old) mdx mice (C57BL/10ScSn-mdx/J; The Jackson Lab-
oratory, Bar Harbor, ME) were injected once at a single site
with 10 or 30 ml, respectively, of Ad vectors in PBS at a titer
ranging from 1.03 1012 to 1.53 1012 virus particles/ml, as de-
scribed previously (Acsadi et al., 1996). At 10 days post-in-
jection, the mice were euthanized by an overdose of pentobar-
bital, and the TA was removed and frozen in liquid
nitrogen-cooled isopentane. Cryostat sections were stained for
dystrophin by immunohistochemistry and for histochemical de-
tection of b-galactosidase as described previously (Acsadi et
al., 1994, 1996). When monoclonal antibodies (see below) were
used on the mouse tissues, the endogenous mouse im-
munoglobulins were first blocked by incubation with an affin-
ity purified goat anti-mouse IgG (Fab fragment, Jackson Im-
muno Research, Mississauga, Ontario, Canada). For each
injected muscle, the total number of transduced fibers (dys-
trophin or b-galactosidase positive) on a single cryostat sec-
tion, which spans the entire TA cross section, was then deter-
mined. For experiments using GRMD dogs, four 4-day-old dogs
(2 normals, 1 carrier and 1 affected) were injected in the right
TA with 100 ml of a mixture of HDAdCMVDysFl and FGAd-
CMV-lacZ at a titer of 1.53 1011 and 1.33 1011 virus parti-
cles/ml respectively. The left extensor carpi radialis (ECR) was
injected with 100 ml of HDAdCMVDysFl alone at a titer of
3.03 1011 virus particles/ml. At 10 days post-injection the in-
jected areas of the muscle were removed and consecutive cryo-
stat sections were stained for dystrophin and counterstained
with hematoxylin, or processed for detection of b-galactosidase
expression. The injection, biopsies, and immunohistochemistry
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were performed as described previously (Howell et al., 1998).
For each injected muscle site, the transduction level was deter-
mined by counting the total number of transduced fibers in the
cryostat sections having the greatest amount of transgene ex-
pression. The following dystrophin antibodies were used for
immunohistochemistry: a rabbit polyclonal antibody raised
against the carboxyl terminus of human dystrophin that recog-
nizes murine, canine, and human dystrophin (Acsadi et al.,
1996); a monoclonal antibody specific for the amino terminus
of human dystrophin (NCL-DYS3, Novocastra, Newcastle
upon Tyne, UK); a monoclonal antibody that recognizes the rod
domain of the murine, canine and human dystrophin (NCL-
DYS1, Novocastra).
Statistical analysis
The data were analyzed using an unpaired two-tailed t-test.
Statistical significance was set at p , 0.05.
RESULTS
Weak dystrophin expression after gene transfer 
with HDAd
For the study of dystrophin expression in muscle after gene
transfer with an Ad vector deleted of all viral genes, a HDAd
encoding the cDNA of the full-length human dystrophin regu-
lated by the CMV promoter was constructed and called HDAd-
CMVDysFl (Fig. 1A). The only viral sequences contained in
this vector are the left and right ITR, as well as the packaging
signal of Ad type 5. To maintain the genome of HDAd-
CMVDysFl to a minimum size that is necessary for efficient
packaging into virus particles (Parks and Graham, 1997), a frag-
ment of 17-kb derived from bacteriophage lambda (lambda
DNA) was included, thus increasing the total vector size to 31
kb. HDAdCMVDysFl was produced and amplified using the
293Cre-loxP system as described previously (Parks et al.,
1996). The DNA of HDAdCMVDysFl was isolated from puri-
fied virus particles and analyzed by digestion with restriction
enzymes (Fig. 2). Apart from minor DNA bands correspond-
ing to less than 6% of the total DNA (Fig. 2B, arrowheads), the
pattern of DNA fragments matches exactly the predicted struc-
ture of HDAdCMVDysFl. The exact nature of the minor con-
taminating bands is not clear. They could be derived from a
small population of vectors generated by recombination of
HDAdCMVDysFl with itself or with the helper virus, a process
known to occur during the production of HDAd (Fisher et al.,
1996; Sandig et al., 2000). The infectious titer of HDAd-
CMVDysFl was measured by infecting 293A cells with vari-
ous vector dilutions. At 20 hr post-infection, the percentage of
cells with vector DNA was determined by in situ hybridization
using probes specific for dystrophin (Fig. 3). As a control, cells
were also infected with FGAdCMV-dys, a FGAd encoding the
minidystrophin cDNA (Fig. 1B) (Acsadi et al., 1996). We found
that the ratio of virus particles, as determined by the optical
density at 260 nm, to the infectious particles, as determined by
in situ hybridization (virus particles:infectious particles) was
comparable (100:1) for both vectors. Similar infectious titers
for HDAdCMVDysFl were obtained using a probe specific for
the lambda DNA (data not shown). Western blot analysis of a
lysate of cells infected with HDAdCMVDysFl demonstrated
that the dystrophin expression cassette carried by this vector
was functional because a dystrophin band of 400 kDa was de-
tected on the blots (see below, Fig. 5).
Dystrophin expression following gene transfer with HDAd-
CMVDysFl in the dystrophin deficient muscle of the mdx mice
was then investigated. The TA of neonatal and adult mdx mice
was injected with 10 or 30 ml, respectively, of a pure prepara-
tion of HDAdCMVDysFl at a titer of 1.03 1012 virus parti-
cles/ml. As control, the TA of adult and neonatal mdx mice
were injected with the same volume and the same titer of FGAd-
CMV-dys. At 10 days post-injection, the injected muscles were
stained for dystrophin and the number of dystrophin-positive
fibers was determined. Unexpectedly, the number of muscle
fibers expressing dystrophin in both neonatal and adult mdx
mice was dramatically higher after the gene transfer with
FGAdCMV-dys than in the HDAdCMVDysFl-injected muscles
(Fig. 4). In addition, after gene transfer with FGAdCMV-dys,
the sarcolemmal signal intensity was stronger, and several mus-
cle fibers contained additional diffuse sarcoplasmic dystrophin
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FIG. 1. Structure of the vectors used in the present study. HDAdCMVDysFl is a HDAd containing a stuffer DNA derived from
bacteriophage lambda and expressing the cDNA of the full-length human dystrophin regulated by the CMV promoter. FGAd-
CMV-dys and FGAdCMV-lacZ are two E1/E3-deleted Ad expressing minidystrophin (Minidys) or b-galactosidase (LacZ), re-
spectively, both transgenes being regulated by the CMV promoter. Ad5/dE1(b-gal)dE4 is an E1/E4-deleted Ad that encodes b-
galactosidase regulated by the mouse phosphoglycerate kinase (pgk) promoter. ITR, Position of the inverted terminal repeats.
staining, a sign of marked dystrophin overexpression (arrows,
Fig. 4A). Such intense diffuse sarcoplasmic dystrophin stain-
ing was not observed in muscles injected with HDAd-
CMVDysFl. The few dystrophin-positive fibers observed after
injection with HDAdCMVDysFl were not revertant fibers of
the mdx muscle that express dystrophin (Hoffman et al., 1990),
because they were stained with a monoclonal antibody that rec-
ognizes the human but not the murine dystrophin (Fig. 4).
Increased dystrophin expression in the presence of Ad
gene products
The previous observations demonstrated that dystrophin was
more efficiently expressed by FGAdCMV-dys, suggesting that
viral gene products encoded by FGAdCMV-dys markedly aug-
ment dystrophin expression. To test this hypothesis, HeLa cells
and C2C12 myotubes were infected with HDAdCMVDysFl
alone or together with FGAd encoding b-galactosidase (FGAd-
CMV-lacZ; Fig. 1C). As a control, cells were infected with
FGAdCMV-dys alone or in the presence of FGAdCMV-lacZ
at the same titer. At 4 days post-infection, the cells were lysed
and analyzed by western blot analysis for the expression of 
dystrophin. Co-infection with FGAdCMV-lacZ dramatically in-
creased the amount of dystrophin produced by HDAd-
CMVDysFl in HeLa cells and C2C12 myotubes (Fig. 5). This
observation suggests that one or more gene product(s) synthe-
sized by FGAdCMV-lacZ could enhance the transgene expres-
sion of an Ad devoid of all viral genes such as HDAd-
CMVDysFl.
To determine if an increase in the number of DNA templates
was responsible for the enhanced dystrophin expression in the
presence of FGAdCMV-lacZ, low-molecular-weight DNA was
isolated from HeLa cells and C2C12 myotubes that were pre-
viously infected 4 days earlier with only HDAdCMVDysFl, or
with HDAdCMVDysFl and FGAdCMV-lacZ. The relative
abundance of vector DNA was then determined by dot blot anal-
ysis using a radio-labeled probe specific for the lambda stuffer
followed by quantification on a phosphoimager (Table 1). Sig-
nificantly more HDAdCMVDysFl DNA was detected in HeLa
cells after co-infection with FGAdCMV-lacZ, whereas no aug-
mentation occurred in C2C12 myotubes. This data indicate that
the enhanced dystrophin expression observed in C2C12 my-
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FIG. 2. Characterization of HDAdCMVDysFl by restriction analysis. (A) Position of the cleavage sites for Eco RI, Kpn I, and
Hind III on the genome of HDAdCMVDysFl. The numbers above and below the bars correspond to the size of the fragments in
kb after digestion with the restriction enzymes. (B) Agarose gel of undigested (uncut) DNA of HDAdCMVDysFl or digested
with Eco RI, Kpn I, and Hind III. M, DNA size marker in kilobases; arrowheads, position of uncharacterized DNA fragments.
otubes in the presence of FGAdCMV-lacZ is not due to an in-
crease in the number of dystrophin DNA templates but is the
result of either enhanced transcription, or RNA transport, or
other post-transcriptional mechanisms. The fact that signifi-
cantly more DNA copies were observed in HeLa cells in the
presence of FGAdCMV-lacZ is in agreement with previous
studies that demonstrated some replication of FGAd in this cell
type because of the existence of E1-like factors. (Dedieu et al.,
1997; Steinwaerder et al., 2000). In addition, the previous data
would suggest that no significant replication of FGAd occurs
in post-mitotic culture of C2C12 myotubes. In the latter cell
line, slightly less DNA was detected in the presence of FGAd-
CMV-lacZ, most likely because of the competition between
FGAdCMV-lacZ and HDAdCMVDysFl for limited number of
receptors at the cell surface. In HeLa cells slightly more dys-
trophin were produced by FGAdCMV-dys in the presence of
FGAdCMV-lacZ (Fig. 5A). This is probably due to the fact that
more efficient DNA replication occurs in HeLa cells at higher
MOI (Steinwaerder et al., 2000), resulting in a proportionally
increase of DNA templates for dystrophin synthesis.
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FIG. 3. Titration of Ad vectors by in situ hybridization. Mock-infected cells (a) or cells infected with FGAdCMV-dys (b) or
HDAdCMVDysFl (c) were processed for in situ hybridization using a probe specific for dystrophin. Arrows, Examples of nu-
clei labeled with viral DNA. Scale bar5 85 mm.
FIG. 4. Higher dystrophin expression in vivo after gene transfer with FGAdCMV-dys compared to HDAdCMVDysFl. The TA
of neonatal and adult mdx mice was injected with 1.03 1012 virus particles/ml of either FGAdCMV-dys or HDAdCMVDysFl.
At 10 days post-injection, the expression of dystrophin was analyzed by immunofluorescence using a monoclonal antibody spe-
cific for the human dystrophin. (A) Cryostat sections of neonatal (a,c) and adult (b,d) muscles injected with FGAdCMV-dys
(a,b) or HDAdCMVDysFl (c,d). Arrows, Muscle fibers with an intense cytoplasmic positive signal (in addition to show sar-
colemmal immunostaining) demonstrating marked dystrophin overexpression. Scale bar5 100 mm. (B) Quantitative analysis of
the number of dystrophin-positive fibers. Bars correspond to the mean6 SEM. N, Number of muscles used for the analysis; *,
means significantly different, p , 0.05.
Having shown that Ad gene products could increase dys-
trophin expression of HDAdCMVDysFl in vitro, we then in-
vestigated if the same applies in vivo. The TA muscle of neona-
tal mdx mice was injected with the same concentration of
HDAdCMVDysFl (1.03 1012 virus particles/ml) spikes with
increased concentration of FGAdCMV-lacZ. At 10 days post-
injection, serial sections of the injected muscles were analyzed
by histochemistry for dystrophin and b-galactosidase expres-
sion and the number of dystrophin positive fibers was deter-
mined (Fig. 6). In agreement with the observation made in vitro,
co-infection with FGAdCMV-lacZ resulted in a significant aug-
mentation in the number of dystrophin-positive fibers. The level
of enhancement was proportional to the amount of FGAdCMV-
lacZ in the preparation and no significant increase was appar-
ent when less than 5% of FGAdCMV-lacZ was present (Fig.
6B). In some muscles, at the highest concentration of FGAd-
CMV-lacZ employed, more than 50% of the muscle fibers were
dystrophin positive and several fibers had, in addition to the
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FIG. 5. Ad gene products increase dystrophin expression of HDAdCMVDysFl in cell culture. HeLa cells (A) or C2C12 my-
otubes (B) were infected with HDAdCMVDysFl (HD), HDAdCMVDysFl and FGAdCMV-lacZ (HD1LacZ), FGAdCMV-dys
(FG), or FGAdCMV-dys and FGAdCMV-lacZ (FG1LacZ). In HeLa cells, the MOI was 2,000 virus particles for HDAd-
CMVDysFl and FGAdCMV-dys, and 10,000 virus particles for FGAdCMV-lacZ. In C2C12, the MOI was the same (10,000 virus
particles) for each vector. At 4 days post-infection, the cells were lysed, and 15 (HeLa) or 30 mg (C2C12) of total protein was
analyzed by western blot using a dystrophin antibody. Cont, Mock-infected cells; arrow, full-length dystrophin; arrowhead, minidy-
strophin. The position of molecular weight marker is indicated on the left of each gel.
TABLE 1. AD GENE PRODUCTS INCREASE THE AMOUNT OF HDADCMVDYSFL IN HELA
CELLS BUT NOT IN C2C12 MYOTUBESa
Amount of HDAdCMVDysFl DNA (arbitrary units)
HeLa cells C2C12 myotubes
Vector tested (mean6 SEM, n 5 3) (mean6 SEM, n5 3)
HDAdCMVDysFl 03.1 6 0.06b 7.86 0.39b
HDAdCMVDysFl
1 593 6 143b 5.36 0.30b
FGAdCMV-lacZ
aHeLa cells or C2C12 myotubes were infected with HDAdCMVDysFl alone or mixed
with FGAdCMV-lacZ. In HeLa cells, the MOI was 20,000 and 10,000 virus particles for
HDAdCMVDysFl and FGAdCMV-lacZ, respectively. In C2C12 myotubes, the MOI was
10,000 virus particles for both vectors. At 4 days post-infection the small nuclear DNA
was extracted and quantified by dot blot analysis using a probe specific for the lambda
stuffer of HDAdCMVDysFl.
bMeans different from cells infected with HDAdCMVDysFl alone, p , 0.05.
strong sarcolemmal dystrophin signal, a diffuse cytoplasmic in-
ternal staining, a sign of marked dystrophin overexpression (ar-
rows Fig. 6A).
To verify that the comparatively lower dystrophin expres-
sion in the muscle injected with pure preparation of HDAd-
CMVDysFl was not due the absence of vector DNA, total DNA
was extracted from muscles injected with pure preparation of
HDAdCMVDysFl and with preparation containing 60% of
FGAdCMV-lacZ. The amount of HDAdCMVDysFl DNA was
measured by semiquantitative PCR using primers specific for
the lambda DNA stuffer as described previously (Chen et al.,
1999). To confirm that the same amount of DNA was used for
the analysis, the unique mouse adipsin gene was amplified si-
multaneously and all values were normalized to the adipsin sig-
nal (Fig. 7A). The muscles injected with pure preparations of
HDAdCMVDysFl contained half the amount of vector DNA
compared to the muscles spiked with 60% FGAdCMV-lacZ
(Fig. 7B). This two-fold difference in the amount of vector DNA
between the two muscle groups is likely to be a negligible fac-
tor responsible for the enhanced dystrophin expression in the
presence of FGAdCMV-lacZ, since the increase in the number
of dystrophin positive fiber was more than one order of mag-
nitude (Fig. 6B).
E4 is required to enhance dystrophin expression
The early region four (E4) of Ad is known to modulate the
transgene expression carried by Ad in vitro and in vivo (Ar-
mentano et al., 1997; Brough et al., 1997; Dedieu et al., 1997;
Lusky et al., 1998). To test if E4 gene products were involved
in enhancing the transgene expression of HDAdCMVDysFl,
cultures of HeLa cells and C2C12 myotubes were infected with
HDAdCMVDysFl spiked with various quantities of an E1/E4-
deleted Ad encoding b-galactosidase (Ad5/dE1(b-gal)dE4, Fig.
1D). As a positive control, cells were also infected with mix-
tures of HDAdCMVDysFl and FGAdCMV-lacZ. At 4 days
post-infection, the cultures were processed by western blots for
dystrophin expression (Fig. 8). Increased dystrophin expression
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FIG. 6. Ad gene products increase dystrophin expression of HDAdCMVDysFl in mdx muscle. The TA of neonatal mdx mice
was injected with various preparations of HDAdCMVDysFl at a titer of 1.0.3 1012 virus particles/ml spiked with 0, 0.1, 1, 5,
or 60% of virus particles of FGAdCMV-lacZ. At 10 days post-injection the muscles were processed by histochemistry to show
dystrophin and b-galactosidase. (A) Serial sections of a muscle injected with HDAdCMVDysFl containing 60% FGAdCMV-
lacZ stained with an antibody specific for dystrophin (a) or processed for b-galactosidase histochemistry (b). Arrows, Muscle
fibers having an intense cytoplasmic dystrophin staining, a sign of marked dystrophin overexpression. Scale bar5 125 mm. (B)
Quantitative analysis of the number of dystrophin-positive fibers in each muscle group. Bars correspond to the mean6 SEM. N,
Number of muscles used for the analysis in each group; *, mean significantly higher compared to pure preparation of HDAd-
CMVDysFl, p , 0.05.
was detected in the presence of FGAdCMV-lacZ but not in the
presence of Ad5/dE1(b-gal)dE4 in both cell types investigated
even at the highest MOI tested. This observation demonstrated
that E4 is required to enhance dystrophin expression, and that
ORF4, the only E4 gene product synthesized by Ad5/dE1(b-
gal)dE4 (Wang et al., 1995, 1997) was insufficient for this func-
tion.
We then tested if E4 products were also required for en-
hancing the transgene expression of HDAdCMVDysFL in vivo.
The TA muscle of neonatal mdx mice was injected with either
HDAdCMVDysFl alone or with a mixture of HDAdCMVDysFl
and Ad5/dE1(b-gal)dE4. At 10 days post-injection, the number
of dystrophin- and b-galactosidase-positive fibers was deter-
mined. The amount of viral DNA in the injected muscle was
also measured by semiquantitative PCR using primer pairs spe-
cific for the lambda stuffer of HDAdCMVDysFl or for the lacZ
gene carried by Ad5/dE1(b-gal)dE4. In agreement with the ob-
servations made in cell culture, the presence of Ad5/dE1(b-
gal)dE4 did not increase the expression of dystrophin by HDAd-
CMVDysFl because the same number of dystrophin-positive
fibers was detected in the two experimental groups (Table 2).
In addition, no difference in the amount of HDAdCMVDysFl
DNA was detected between the two groups. The incapacity of
Ad5/dE1(b-gal)dE4 to increase dystrophin expression was not
due to the lack of vector in the muscle, because b-galactosi-
dase-positive fibers were detected as well as a significant quan-
tity of vector DNA (Table 2).
Ad gene products enhance dystrophin expression from
HDAdCMVDysFl in GRMD dogs
Having demonstrated that co-infection with a FGAd in-
creases the expression of dystrophin carried by a HDAd in the
muscles of mdx mice, we then investigated if the same result
occurs in the muscle of another animal model for DMD, the
dystrophin-deficient GRMD dogs. The absence of dystrophin
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FIG. 7. Lower transgene expression by HDAdCMVDysFl in muscle is not due to loss of vector DNA. Total DNA was iso-
lated from cryostat sections of muscles injected with HDAdCMVDysFl (1.0 3 1012 virus particles/ml) or with the same titer of
HDAdCMVDysFl containing 60% of FGAdCMV-lacZ. The same quantity of total DNA from six different muscles in each group
was amplified by PCR using primers specific for the lambda DNA stuffer (Lamb) or for the adipsin gene (Adi). (A) Agarose gel
of the PCR products. Ctrl, PCR reaction using DNA of uninjected muscle; water, PCR reaction without DNA. (B) Quantifica-
tion of the PCR products using primers specific for lambda. Bars correspond to the mean6 SEM. N, Number of muscles used
for the analysis; *, mean significantly different, p , 0.05.
in this animal model, unlike the mdx mice, leads to a clinico-
pathological phenotype similar to that of DMD (Valentine et
al., 1992). The left extensor carpi radialis (ECR) of a 4-day-
old dystrophin deficient GRMD dog was injected with 100 ml
of HDAdCMVDysFl and the right TA with 100 ml of a mix-
ture of HDAdCMVDysFl spiked with FGAdCMV-lacZ. At 10
days post-injection, biopsies of the injected sites were taken and
analyzed for dystrophin and b-galactosidase expression. The
maximal number of dystrophin positive fibers at the injection
site was 46 in the muscle injected with only HDAdCMVDysFl,
whereas it was 1,101 in the muscle injected with the mixture
of the two vectors (Fig. 9). In the latter group, the area con-
taining the dystrophin-positive fibers was also positive for b-
galactosidase (Fig. 9C). When the same experiment was car-
ried out in normal and carrier dogs (both animals express
dystrophin), muscle fibers expressing the human recombinant
dystrophin (total was 39) were detected only in the muscles in-
jected with the mixture of HDAdCMVDysFl and FGAdCMV-
lacZ. In the last experiment, the human dystrophin protein was
distinguished from the endogenous canine dystrophin by stain-
ing the sections with a human-specific antibody (DYS3). In our
hands this antibody was less efficient for detecting the trans-
duced fibers in comparison to DYS1, the antibody used to stain
the affected dogs. In addition, the transduced fibers in the nor-
mal and carrier dogs could have been underestimated because
of a competition between the endogenous and recombinant dys-
trophin for limited binding sites at the sarcolemma. In other
words, only the very highly transduced fibers could be detected
by immunohistochemistry, because the dystrophin binding sites
were already occupied by the endogenous dystrophin. Taken
together, these data demonstrate that gene products encoded by
FGAd could significantly increase the expression of dystrophin
carried by a HDAd in mdx mice as well as the GRMD dog,
two animal models of DMD.
DISCUSSION
To be effective as treatment for DMD or other genetic dis-
eases, a therapy based on a gene transfer strategy requires ef-
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FIG. 8. E4 gene products are essential to increase dystrophin expression from HDAdCMVDysFl in cell culture. HeLa cells (A)
or C2C12 myotubes (B) were infected with HDAdCMVDysFl at an MOI of 10,000 virus particles spiked with various amounts
of FGAdCMV-lacZ, or Ad5/dE1(b-gal)dE4 at the indicated MOI in virus particles. At 4 days post-infection, the cells were
processed for western blot using a dystrophin-specific antibody.
TABLE 2. E4 IS REQUIRED TO INCREASE DYSTROPHIN EXPRESSION OF HDADCMVDYSFL IN VIVO
Number of Number of Number of copies of Number of copies of
Dys1 fibers b-gal1 fibers HDAdCMCVDysFl Ad5/dE1(b-gal)dE4
per muscle per muscle per 100 ng total DNAb per 100 ng total DNAc
Vectors testeda (mean6 SEM) (mean6 SEM) (mean6 SEM) (mean6 SEM)
HDAdCMVDysFl 54.56 31.6 Not applicable 77546 1247 (n 5 5) Not applicable
(n 5 12)d
HDAdCMVDysFl
1 37.8.26 19.4 60.26 40.4 76496 1744 (n 5 5) 30356 865.6 (n 5 5)
Ad5/dE1(b-gal)dE4 (n 5 12) (n 5 12)
aThe TA of neonatal mdx mice was injected with pure HDAdCMVDysFl at a titer of 1.53 1012 virus particles/ml or with a
mixture of HDAdCMVDysFl and Ad5/dE1(b-gal)dE4 at the a titer of 1.53 1012 and 1.13 1012 virus particles/ml, respectively.
The injected muscles were analyzed at 10 days post-injection.
bAs determined by semiquantitative PCR using primers specific for the lambda stuffer.
cAs determined by semiquantitative PCR using primers specific for b-galactosidase.
dNumber of muscles used for the analysis.
ficient and high-level prolonged transgene expression. Effi-
cient, but temporary, transgene expression has been achieved
after gene transfer with FGAd in many tissues of the body, in-
cluding muscle. The transgene antigenicity and the immune re-
sponse triggered by low-grade synthesis of Ad gene products
have been both demonstrated to be responsible for the transient
nature of the transgene expression (Yang et al., 1994a,b; Tri-
pathy et al., 1996; Yang et al., 1996; Michou et al., 1997). In
an attempt to solve the problem caused by the low grade viral
synthesis, Ad vectors deleted of all viral genes have been de-
veloped. The use of these vectors has resulted in as significant
improvement in the duration of the transgene expression in var-
ious tissues including muscle (Morsy et al., 1998; Schiedner et
al., 1998; Chen et al., 1999; Maione et al., 2000; Zou et al.,
2000). In the present study, we have compared dystrophin ex-
pression after gene transfer with a FGAd (FGAdCMV-dys) and
a fully deleted HDAd (HDAdCMVDysFl) carrying the full dys-
trophin cDNA. Although dystrophin was regulated by the same
CMV promoter, significantly more dystrophin was produced af-
ter gene transfer with FGAdCMV-dys both in vitro and in vivo.
We then demonstrated that the comparatively higher transgene
expression bestowed by FGAdCMV-dys was due to the pres-
ence of Ad gene products that could act in trans to enhance the
transgene expression of HDAdCMVDysFl in cell culture and
in the skeletal muscle of mdx mice and GRMD dogs, two an-
imal models for DMD. This ruled out that a defective vector or
a defective expression cassette was responsible for the weaker
dystrophin expression observed after gene transfer with HDAd-
CMVDysFl.
Our data are in agreement with the observation made by sev-
eral groups that a significant reduction in transgene expression
occurs after gene transfer with E1/E4-deleted Ad compared to
FGAd (Armentano et al., 1997; Brough et al., 1997; Dedieu et
al., 1997; Lusky et al., 1998, 1999; Armentano et al., 1999;
Grave et al., 2000). A significant loss of transgene expression
was also described after gene transfer with a partly deleted mini-
Ad in the liver (Lieber et al., 1996,1997). However, it is un-
clear why similar reduction in transgene expression was not de-
scribed by many researchers who have compared HDAd and
FGAd in various tissues (Morsy et al., 1998; Schiedner et al.,
1998; Chen et al., 1999; Maione et al., 2000; Zou et al., 2000).
It is possible that the requirement for Ad gene products to aug-
ment the transgene expression in HDAd vectors is tissue spe-
cific. The nature of the stuffer carried by the HDAd may have
also reduced the transgene expression (Parks et al., 1999) (see
below). It is also possible that the Ad gene products exert their
action mainly when the transgene is regulated by ubiquitous
cellular promoters or strong viral promoters such as CMV
(Grave et al., 2000). In this respect, a significant increase of
dystrophin expression by a fully deleted HDAd regulated by
the hybrid CMV enhancer/b-actin promoter, without lambda
stuffer, was observed when co-injected with a FGAd in mdx
muscle (data not shown). This indicates that other promoters
besides the CMV promoter could be up-regulated by trans-act-
ing Ad gene products. Experiments are currently in progress to
determine if the up-regulation will occur when tissue-specific
eukaryotic promoters, such as the muscle creatine kinase pro-
moter, are employed.
An all-important question is the molecular mechanism(s) by
which the Ad gene product(s) augment markedly the transgene
expression in the context of a HD (“fully gutted”) Ad. We ob-
served that co-administration of an E1/E4-deleted Ad
(Ad5/dE1(b-gal)dE4) was unable to increase dystrophin ex-
pression of HDAdCMVDysFl in cell culture and in muscle in
vivo. The E4 region contains seven potential open reading
frames encoding proteins of various biochemical functions (for
review, see Leppard, 1997). One of them, ORF4, had no effect
on the transgene expression, because it is encoded by
Ad5/dE1(b-gal)dE4, which did not increase the expression of
dystrophin by HDAdCMVDysFl in vitro and in vivo. The mech-
anism by which E4 gene products enhance the transgene ex-
pression is not clear, and several nonexclusive mechanisms are
possible. For example, in the lung, E4 gene product (ORF3)
has been suggested to stabilize the transgene expression by in-
activating a transcriptional repressor of the CMV promoter (Ar-
mentano et al., 1999; Yew et al., 1999). In cell culture, a re-
duction in the initiation of transcription rate of the transgene
has been reported in the absence of E4 (Lusky et al., 1999;
Grave et al., 2000). ORF6 and ORF3 are known to increase late
viral gene expression by favoring the accumulation of late vi-
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FIG. 9. Ad gene products increase dystrophin expression of HDAdCMVDysFl in muscle of GRMD dog. The left ECR of a 4-
day-old affected GRMD dog was injected with HDAdCMVDysFl (3.03 1011 virus particles/ml) or the right TA with a mixture
of HDAdCMVDysFl and FGAdCMV-lacZ at a titer of 1.53 1011 and 1.33 1011 virus particles/ml, respectively. At 10 days
post-injection, cryostat sections of the injected muscle sites were processed for dystrophin (A,B) and b-galactosidase (C) ex-
pression. (A) Section of a muscle injected with only HDAdCMVDysFl showing few dystrophin positive fibers (arrows). (B) Sec-
tion of a muscle injected with a mixture of HDAdCMVDysFl and FGAdCMV-lacZ and demonstrating abundant dystrophin pos-
itive fibers. (C) Section of the same region as B demonstrating abundant b-galactosidase expression. Scale bar5 160 mm.
ral RNA and their transport to the cytoplasm (for review, see Im-
periale et al., 1995). Deletion of E4 in the backbone of a FGAd
leads to a reduction of early and late protein synthesis (Dedieu
et al., 1997; Lusky et al., 1998). Consequently, the weaker trans-
gene expression in the absence of E4 could be due to the sec-
ondary absence of early and late adenoviral gene products.
The presence of FGAdCMV-lacZ in C2C12 did not increase
the amount of vector DNA. This indicates that the low level of
viral replication or stabilization of the vector DNA were not the
mechanisms by which dystrophin expression of HDAd-
CMVDysFl was enhanced. After gene transfer in mdx muscle,
about two times more HDAdCMVDysFl DNA was detected in
the presence of FGAdCMV-lacZ. The fact that the number of
dystrophin-positive fibers was more than one order of magni-
tude higher in the presence of FGAdCMV-lacZ, indicates that
this small increase in DNA templates was not a significant
mechanism by which enhanced dystrophin expression was
achieved. The augmentation of vector DNA in the presence of
FGAdCMV-lacZ could be due to low viral replication level or
to the stabilization of vector DNA. Further studies will be re-
quired to resolve these issues because both processes have been
described in vivo (Lieber et al., 1996, 1997). During the course
of evolution, it is likely that the naturally occurring Ad has de-
veloped complementary mechanisms to optimize the expression
of its episomal genome.
The nature of the stuffer has been shown to modulate the
transgene expression of a HDAd (Parks et al., 1999). A more
robust transgene expression was observed after gene transfer in
the liver with a HDAd made with a stuffer DNA derived from
a genomic fragment of hypoxanthine-guanine phosphoribosyl-
transferase (HPRT) in comparison to a stuffer derived from
phage lambda. This suggests that some uncharacterized prop-
erties of this stuffer could compensate for the absence of ade-
noviral gene products. Thus, we could speculate that the inclu-
sion of an improved stuffer, in conjunction with certain
adenoviral genes, could further improve the efficacy of the
transgene expression of HDAd. However we have to be cau-
tious because inclusion of Ad genes in the HDAd vector could
result in the reemergence of some deleterious immunogenicity.
This could be partly or totally controlled if the viral genes were
regulated by weak or muscle specific promoters, or by inducible
promoters for transient expression when needed. The experi-
ments of this study were accomplished using young animals
whose muscles are transduced more efficiently than adult mus-
cles (Huard et al., 1995). Even with an optimized HDAd, it
might be difficult to transduce mature muscle fibers. However,
several parameters such as the tropism of the vector (Bouri et
al., 1999), the route of administration (Cho et al., 2000), or the
quantity of Ad receptors on the muscle fibers (Nalbantoglu et
al., 2001), could be modified to ameliorate the transduction
level in adult animals.
In conclusion, we have demonstrated that Ad gene products
can significantly increase the transgene expression carried by a
HDAd. This observation was made in cell culture and in the
muscle of mdx mice and GRMD dogs, two animal models for
DMD. The characterization of these adenoviral gene products,
followed by their inclusion into an optimized HDAd, might be
necessary to generate a vector capable of synthesizing enough
dystrophin to correct or mitigate the pathology associated with
dystrophin deficiencies.
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